Unknown

Dataset Information

0

Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.


ABSTRACT: Anti-apoptotic BCL-2 family proteins block cell death by trapping the critical ?-helical BH3 domains of pro-apoptotic members in a surface groove. Cancer cells hijack this survival mechanism by overexpressing a spectrum of anti-apoptotic members, mounting formidable apoptotic blockades that resist chemotherapeutic treatment. Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2-dependent cancers. BFL-1 is a BCL-2 homolog implicated in melanoma, lymphoma, and other cancers, and remains undrugged. A natural juxtaposition of two unique cysteines at the binding interface of the NOXA BH3 helix and BFL-1 pocket informed the development of stapled BH3 peptides bearing acrylamide warheads to irreversibly inhibit BFL-1 by covalent targeting. Given the frequent proximity of native cysteines to regulatory binding surfaces, covalent stapled peptide inhibitors provide a new therapeutic strategy for targeting pathologic protein interactions.

SUBMITTER: Huhn AJ 

PROVIDER: S-EPMC5055752 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.

Huhn Annissa J AJ   Guerra Rachel M RM   Harvey Edward P EP   Bird Gregory H GH   Walensky Loren D LD  

Cell chemical biology 20160908 9


Anti-apoptotic BCL-2 family proteins block cell death by trapping the critical α-helical BH3 domains of pro-apoptotic members in a surface groove. Cancer cells hijack this survival mechanism by overexpressing a spectrum of anti-apoptotic members, mounting formidable apoptotic blockades that resist chemotherapeutic treatment. Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in re  ...[more]

Similar Datasets

| S-EPMC5947960 | biostudies-literature
2015-08-13 | E-GEOD-72031 | biostudies-arrayexpress
2016-05-19 | GSE72031 | GEO
2016-08-29 | GSE72022 | GEO
2022-12-31 | GSE215335 | GEO
| S-EPMC4265651 | biostudies-literature
| S-EPMC7405809 | biostudies-literature
2016-05-19 | GSE72023 | GEO
| S-EPMC5033074 | biostudies-literature
| S-EPMC3366394 | biostudies-literature